Skip Navigation

Staff Detail

Skip sharing on social media links

​​​

Moye, Jack

Formal Title:

Medical Officer

Responsibilities:

Director of Repository and Laboratories and Acting Director National Children's Study

Phone:

301-594-8624

Email:

moyej@mail.nih.gov

Address:

6100 EXECUTIVE BLVD Room 3A01, MSC 7510
Bethesda Md 20892-7510
For FedEx use:
Rockville Md 20852

Biosketch:

Jack Moye, Jr., MD is a pediatrician and former state public health laboratory official who joined the National Children's Study Program Office to serve as Senior Scientist and Director of Repository and Laboratories.  He came to the National Children's Study from within the Eunice Kennedy Shriver National Institute of Child Health and Human Development, where from 1991–2007 he was a member of the Pediatric, Adolescent, and Maternal AIDS Branch in the Center for Research for Mothers and Children. There his areas of responsibility included laboratory quality assurance, biospecimen repository management, virology and immunology research, epidemiologic cohort studies and clinical trials, growth and nutrition, and international research initiatives. His background is in clinical and laboratory medicine and in preventive medicine and public health, with emphasis on prevention and control of communicable and chronic diseases, including sexually transmitted diseases and HIV/AIDS. He is a member of the research team that conducted AIDS Clinical Trials Group protocol 076 (ZDV to prevent mother-to-child HIV transmission) and has been a member of panels and task forces for the U.S. Public Health Service Surgeon General, the U.S. Conference of Mayors, the New England Governors Conference, and the Massachusetts Governor, and a consultant to state and city departments of health, social services, corrections, youth services, and education.

Publications (PubMed):

Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
Predictors of resolution and persistence of renal laboratory abnormalities in pediatric HIV infection.
Early viral suppression improves neurocognitive outcomes in HIV-infected children.
Medication adherence in children and adolescents with HIV infection: associations with behavioral impairment.
Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection.
Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection.
The utility of IgA antibody to human immunodeficiency virus type 1 in early diagnosis of vertically transmitted infection. National Institute of Allergy and Infectious Diseases and National Institute of Child Health and Human Development Women and Infants Transmission Study Group.
Interlaboratory variability of CD8 subset measurements by flow cytometry and its applications to multicenter clinical trials. NAID/NICHD Women and Infants Transmission Study Group.
Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.
Nevirapine concentrations in newborns receiving an extended prophylactic regimen.
Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia.
Endocrine abnormalities and impaired growth in human immunodeficiency virus-infected children.
Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV.
Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection.
Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis.
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.
Bioelectrical impedance analysis models for prediction of total body water and fat-free mass in healthy and HIV-infected children and adolescents.
Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.
Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.
Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs.
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C.
Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402.
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection.
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Syphilis in HIV-infected Mothers and Infants: Results from the NICHD/HPTN 040 Study.
Laboratory abnormalities among HIV-1-infected pregnant women receiving antiretrovirals in Latin America and the Caribbean.
Current issues in the immunoprophylaxis of vertical transmission of HIV.
Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218).
Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Urinary concentrations of environmental phenols in pregnant women in a pilot study of the National Children's Study.
Iodine status in pregnant women in the National Children's Study and in U.S. women (15-44 years), National Health and Nutrition Examination Survey 2005-2010.
Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.
Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV.
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
Selected persistent organic pollutants in human placental tissue from the United States.
Planned variation in preanalytical conditions to evaluate biospecimen stability in the National Children's Study (NCS).
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.
The use of human tissues in research: what do we owe the research subjects?
Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy.
Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.
Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.
Randomized controlled trial of feeding a concentrated formula to infants born to women infected by human immunodeficiency virus.
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
Insulin-like growth factor-1 and lean body mass in HIV-infected children.
Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.
Cohort Profile: NICHD International Site Development Initiative (NISDI): a prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countries.
Interventions to prevent vertical transmission of HIV-1: effect on viral detection rate in early infant samples.
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.
Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Serum vitamin A concentrations in a North American cohort of human immunodeficiency virus type 1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group.
Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection.
The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
Perinatally acquired human immunodeficiency virus infection: extent of clinical recognition in a population-based cohort. Massachusetts Pediatric HIV Surveillance Working Group.
Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children.
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.
Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children.
Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. The Women and Infant Transmission Study Group.
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment.
Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group.
HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.
A comparison of peripheral blood coculture versus 18- or 24-month serology in the diagnosis of human immunodeficiency virus infection in the offspring of infected mothers. Women and Infants Transmission Study.
Diagnosis of infection with human immunodeficiency virus type 1 by a DNA polymerase chain reaction assay among infants enrolled in the Women and Infants' Transmission Study.
Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. Women and Infants Transmission Study Group.
Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.
Immune complex-dissociated p24 antigen in congenital or perinatal HIV infection: role in the diagnosis and assessment of risk of infection in infants.
Lymphocyte phenotyping in infants: maturation of lymphocyte subpopulations and the effects of HIV infection.
Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. Women and Infants Transmission Study (WITS).
After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group.
Prenatal mercury concentration is associated with changes in DNA methylation at TCEANC2 in newborns.
Tuberculosis in human immunodeficiency virus-exposed or -infected United States children.
Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection. The Women and Infants Transmission Study Group.
Misdiagnosed HIV infection in pregnant women: implications for clinical care.
Manipulating the immune system with immune globulin. The National Institute of Child Health and Human Development. Intravenous Immunoglobulin Study Group.
Success rates for consent and collection of prenatal biological specimens in an epidemiologic survey of child health.
Exploring the associations between microRNA expression profiles and environmental pollutants in human placenta from the National Children's Study (NCS).
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology